MedTrace Logo

Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis

NCT03018925 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

This study aims to characterize the changes on intestinal microbiota pattern associated with the use of golimumab in order to determine if intestinal microbiota markers may correlate with golimumab therapeutic effect in patients naïve \& non-naïve to anti-TNF treatment

Conditions

Interventions

DRUG

Golimumab

The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.

Sponsors & Collaborators

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    lead OTHER

Principal Investigators

  • Xavier XA Aldeguer, Dr. · Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-03-31
Completion
2020-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03018925 on ClinicalTrials.gov